Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
Public ClinicalTrials.gov record NCT03427814. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-blind, Randomized Study of BGB-290 Versus Placebo as Maintenance Therapy in Patients With Inoperable Locally Advanced or Metastatic Gastric Cancer That Responded to Platinum-based First-line Chemotherapy
Study identification
- NCT ID
- NCT03427814
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- BeiGene
- Industry
- Enrollment
- 136 participants
Conditions and interventions
Conditions
Interventions
- Pamiparib Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2, 2018
- Primary completion
- Jun 17, 2020
- Completion
- Jan 2, 2023
- Last update posted
- Oct 25, 2024
2018 – 2023
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Scri Florida Cancer Specialist East | West Palm Beach | Florida | 33401 | — |
| Goshen Center For Cancer Care | Goshen | Indiana | 46526 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40217 | — |
| Novant Health Hematology Charlotte | Charlotte | North Carolina | 28204 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03427814, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2024 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03427814 live on ClinicalTrials.gov.